Trevi Therapeutics logo

Trevi Therapeutics Share Price Today

(NASDAQ: TRVI)

Trevi Therapeutics share price is $4.24 & ₹370.68 as on 8 Feb 2025, 2.30 'hrs' IST

$4.24

-0.02

(-0.47%)

Market is closed - opens 8 PM, 10 Feb 2025

View live Trevi Therapeutics share price in Dollar and Rupees. Guide to invest in Trevi Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Trevi Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Trevi Therapeutics share price movements

  • Today's Low: $4.13
    Today's High: $4.35

    Day's Volatility :5.13%

  • 52 Weeks Low: $1.52
    52 Weeks High: $4.68

    52 Weeks Volatility :67.55%

Trevi Therapeutics (TRVI) Returns

PeriodTrevi Therapeutics IncIndex (Russel 2000)
3 Months
38.11%
0.0%
6 Months
55.31%
0.0%
1 Year
139.55%
0.0%
3 Years
79.66%
-15.1%

Trevi Therapeutics (TRVI) Key Statistics

in dollars & INR

Previous Close
$4.26
Open
$4.25
Today's High
$4.3499
Today's Low
$4.1268
Market Capitalization
$380.7M
Today's Volume
$480.1K
52 Week High
$4.68
52 Week Low
$1.5187
Revenue TTM
$0.0
EBITDA
$-48.1M
Earnings Per Share (EPS)
$-0.44
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-59.65%

How to invest in Trevi Therapeutics Stock (TRVI) from India?

It is very easy for Indian residents to invest directly in Trevi Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Trevi Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Trevi Therapeutics or TRVI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Trevi Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Trevi Therapeutics shares which would translate to 0.206 fractional shares of Trevi Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Trevi Therapeutics, in just a few clicks!

Returns in Trevi Therapeutics (TRVI) for Indian investors in Rupees

The Trevi Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Trevi Therapeutics investment value today

Current value as on today

₹2,44,879

Returns

₹1,44,879

(+144.88%)

Returns from Trevi Therapeutics Stock

₹1,39,548 (+139.55%)

Dollar Returns

₹5,331 (+5.33%)

Indian investors sentiment towards Trevi Therapeutics (TRVI)

-66%

Period: Jan 10, 2025 to Feb 9, 2025. Change in 30 Days versus previous period

Search interest for Trevi Therapeutics Stock from India on INDmoney has decreased by -66% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Trevi Therapeutics

  • NEA Management Company, LLC

    12.72%

  • Rubric Capital Management LP

    5.63%

  • Viking Global Investors LP

    4.92%

  • VR Adviser, LLC

    3.83%

  • Vanguard Group Inc

    3.65%

  • BlackRock Inc

    3.61%

Analyst Recommendation on Trevi Therapeutics

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Trevi Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Trevi Therapeutics Stock (TRVI)

What analysts predicted

Upside of 134.54%

Target:

$9.94

Current:

$4.24

Insights on Trevi Therapeutics Stock (Ticker Symbol: TRVI)

  • Price Movement

    In the last 7 days, TRVI stock has moved up by 7.6%

Trevi Therapeutics Technicals Summary

Sell

Neutral

Buy

Trevi Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Trevi Therapeutics (TRVI) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trevi Therapeutics Inc logo
10.99%
55.31%
139.55%
79.66%
79.66%
Biontech Se logo
-4.27%
45.88%
25.3%
-31.2%
297.87%
Regeneron Pharmaceuticals, Inc. logo
1.88%
-36.67%
-25.03%
11.21%
74.75%
Vertex Pharmaceuticals Incorporated logo
14.59%
1.04%
12.14%
100.66%
93.77%
Alnylam Pharmaceuticals, Inc. logo
16.06%
2.22%
63.1%
83.2%
106.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trevi Therapeutics Inc logo
NA
NA
NA
-0.48
-0.6
-0.37
NA
0.78
Biontech Se logo
160.8
NA
0.04
-3.29
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
18.83
18.83
1.15
43.84
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.28
0.48
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trevi Therapeutics Inc logo
Buy
$380.7M
79.66%
NA
0.0%
Biontech Se logo
Buy
$28.8B
297.87%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$78.9B
74.75%
18.83
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$123.9B
93.77%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$35.9B
106.13%
NA
-15.86%

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Organization
Trevi Therapeutics
Employees
27
CEO
Ms. Jennifer L. Good
Industry
Pharmaceuticals: Major

Management People of Trevi Therapeutics

NameTitle
Ms. Jennifer L. Good
Co-Founder, CEO, President & Director
Dr. Thomas R. Sciascia M.D.
Co-Founder & Chief Scientific Officer
Dr. James V. Cassella Ph.D.
Chief Development Officer
Ms. Lisa Delfini
Chief Financial Officer
Mr. Christopher Galletta
Controller & Chief Accounting Officer
Katie McManus
Communications Manager
Mr. Farrell Simon Pharm.D.
Chief Commercial Officer
Ms. Danine Summers
Vice President of Medical Affairs

Important FAQs about investing in TRVI Stock from India :

What is Trevi Therapeutics share price today?

Trevi Therapeutics share price today stands at $4.24, Open: $4.25 ; Previous Close: $4.26 ; High: $4.35 ; Low: $4.13 ; 52 Week High: $4.68 ; 52 Week Low: $1.52.

The stock opens at $4.25, after a previous close of $4.26. The stock reached a daily high of $4.35 and a low of $4.13, with a 52-week high of $4.68 and a 52-week low of $1.52.

Can Indians buy Trevi Therapeutics shares?

Yes, Indians can invest in the Trevi Therapeutics (TRVI) from India.

With INDmoney, you can buy Trevi Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Trevi Therapeutics at zero transaction cost.

How can I buy Trevi Therapeutics shares from India?

It is very easy to buy Trevi Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Trevi Therapeutics (TRVI) be purchased?

Yes, you can buy fractional shares of Trevi Therapeutics with INDmoney app.

What are the documents required to start investing in Trevi Therapeutics stocks?

To start investing in Trevi Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Trevi Therapeutics Stock (TRVI)?

Today’s highest price of Trevi Therapeutics (TRVI) is $4.35.

Today’s lowest price of Trevi Therapeutics (TRVI) is $4.13.

What is today's market capitalisation of Trevi Therapeutics?

Today's market capitalisation of Trevi Therapeutics TRVI is 380.7M

What is the 52 Week High and Low Range of Trevi Therapeutics Stock (TRVI)?

  • 52 Week High

    $4.68

  • 52 Week Low

    $1.52

What are the historical returns of Trevi Therapeutics (TRVI)?

  • 1 Month Returns

    10.99%

  • 3 Months Returns

    55.31%

  • 1 Year Returns

    139.55%

  • 5 Years Returns

    79.66%

Who is the Chief Executive Officer (CEO) of Trevi Therapeutics ?

Ms. Jennifer L. Good is the current Chief Executive Officer (CEO) of Trevi Therapeutics.